P2RX7

P2X purinoreceptor 7

Score: 0.682 Price: $0.68 High Druggability Status: active Wiki: P2RX7

🧠 Neurodegeneration

HYPOTHESES

1

PAPERS

29

KG EDGES

155

DEBATES

1

3D Protein Structure

🧬 P2RX7 — PDB 5U1L Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

Druggability & Clinical Context

Druggability

High

Score: 0.80

Clinical Stage

Phase II

Target Class

Ion Channel

Safety

0.60

Druggability Analysis

Drug Development0.30

Structural Tractability0.85

Target Class0.85

Safety Profile0.60

Key Metrics

PDB Structures:

24

Known Drugs:

2

Approved:

0

In Clinical Trials:

0

Drug Pipeline (2 compounds)

2 Preclinical

Druggability Rationale: P2X7 is highly druggable due to its well-characterized ATP-binding pocket, extensive structural data (24 PDB structures with sub-angstrom resolution), and proven clinical precedent with multiple selective antagonists in Phase 2 trials. The ion channel architecture provides a clearly defined ligand-binding site, and the high druggability score (0.80) reflects established chemical matter and successful target validation in inflammatory and neuropsychiatric indications.

Mechanism: Selective P2X7 receptor antagonists blocking ATP-gated ion channel

Drug Pipeline (2 compounds)

2 Preclinical

Known Drugs:

A-804598 (investigational) — inflammatory diseases

JNJ-54175446 (investigational) — depression

Structural Data:

PDB (24) ✓AlphaFold ✓Cryo-EM —

5U1L 5U1U 5U1V 5U1W 5U1X+19 more

UniProt: Q0IJ51

Selectivity & Safety Considerations

P2X7 selectivity over closely related P2X family members (P2X1-P2X6) is achievable but requires careful structural optimization, as antagonists may show cross-reactivity with other purinergic receptors. The unique C-terminal domain and specific ATP-binding pocket geometry of P2X7 provide selectivity advantages, though off-target effects on other ATP-sensing proteins should be monitored during development.

3D Protein Structure

PDB: Open in RCSB AlphaFold model

Interactive 3D viewer powered by RCSB PDB / Mol*. Use mouse to rotate, scroll to zoom.

Clinical Trials (8)

Relevant trials from ClinicalTrials.gov

Active

1

Completed

7

Total Enrollment

860

By Phase

NA: 5 · PHASE1: 1 · PHASE2: 1 · Unknown: 1

Anger Control Training for Youth With Tourette Syndrome Completed

NA NCT00486551 n=26

Tourette Syndrome, Chronic Tic Disorder, Oppositional Defiant Disorder

Interventions: Anger control training

Sponsor: Yale University | Started: 2001-08

Adaptive vs. Continuous Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease Recruiting

NA NCT06909045 n=130

Deep Brain Stimulation, Parkinson Disease

Interventions: Adaptive DBS, Continue DBS

Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC | Started: 2026-01-27

Expiratory Muscle Training in Patients With Parkinson's Disease Completed

PHASE1 NCT00843739 n=90

Parkinson's Disease

Interventions: EMST - Active Treatment, sham EMST

Sponsor: University of Florida | Started: 2004-01

Study of the Follow-up of Stroke Treated With Anticoagulants Completed

Unknown NCT03292575 n=441

Stroke

Interventions: Anticoagulants

Sponsor: Centre Hospitalier Universitaire Dijon | Started: 2016-01

Early Detection and Prevention of Mild Cognitive Impairment Due to Cerebrovascular Disease Completed

NA NCT01924312 n=80

Cerebrovascular Disease, Mild Cognitive Impairment

Interventions: Heart Health Intervention

Sponsor: Gregory Jicha, 323-5550 | Started: 2013-05

Effects of Modern Board Games on Well Being in Older Adults Completed

NA NCT06306365 n=35

Executive Functions

Interventions: Modern board game-based learning

Sponsor: European University Miguel de Cervantes | Started: 2024-02-07

Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol Completed

NA NCT02260167 n=25

Alzheimer's Disease, Dementia

Interventions: A mix of natural treatments and medicati

Sponsor: Practitioners Alliance Network | Started: 2014-09

A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2) Completed

PHASE2 NCT03987295 n=33

Frontotemporal Dementia

Interventions: AL001

Sponsor: Alector Inc. | Started: 2019-09-27

Linked Hypotheses (1)

P2RX7-Mediated Exosome Secretion Blockade0.552

Linked Experiments (1)

P2RX7 variant rs1718119 association with glucose homeostasis in Botnia cohort0.900

Scoring Dimensions

Knowledge Graph (20)

associated with (1)

P2RX7→neurodegeneration

co discussed (17)

BMAL1→P2RX7HK2→P2RX7MIRO1→P2RX7P2RY1→P2RX7SOAT1→P2RX7

▸ Show 12 more

KCNK2→P2RX7TET2→P2RX7PIEZO1→P2RX7P2RX7→DGAT1P2RX7→C3NTN1→P2RX7HSPG2→P2RX7P2RY12→P2RX7P2RX7→AQP4P2RX7→EPHB4P2RX7→SMPD1P2RX7→C1QA

interacts with (2)

P2RY1→P2RX7P2RX7→P2RY1

Debate History (1)

Should P2RX7 (P2X purinoreceptor 7) be prioritized as a therapeutic target for n2026-04-21